Recovery
TB-500
Thymosin beta-4 fragment
TB-500 is a synthetic peptide based on a short fragment of thymosin beta-4, a protein the body uses in tissue repair. It is discussed for recovery, but the product itself has almost no published human research.
Key facts
- Commonly discussed for: wound healing and soft-tissue recovery.
- Evidence (D): Human trials used full-length thymosin beta-4, not TB-500: for example a 9-patient phase 2 dry-eye trial and a 40-person IV safety study. Anti-doping chemists identified TB-500 as containing a 7-amino-acid fragment, and no controlled human trial of that product has been published.
- FDA status: PCAC recommended. After TB-500 left FDA's Category 2 list in April 2026, the PCAC voted 8-6 (1 abstention) on July 23, 2026 to recommend it for the 503A Bulks List for wound healing. In a notice published Oct 30, 2026, HHS said it does not intend to take enforcement action against licensed pharmacies and physicians compounding it under set conditions while the FDA writes rules. That is interim enforcement discretion, not FDA approval, and the FDA had not proposed adding it to the list as of Nov 18, 2026.
- Legitimate access: Prescription compounding under an interim HHS policy (not FDA-approved).
- Last reviewed: October 1, 2026.
Read the deep dives
Sources
- Esposito et al. Characterization of the thymosin beta 4 fragment identified in TB-500. Drug Test Anal, 2012
- Sosne et al. Thymosin beta 4 improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea, 2015
- Ruff et al. Randomized, placebo-controlled study of intravenous thymosin beta 4 in healthy volunteers. Ann N Y Acad Sci, 2010
- McDermott Will & Schulte: PCAC backs majority of peptides in two-day public meeting (July 2026)
- Federal Register notice of PCAC meeting and uses under review (April 16, 2026)